Show results for
Refine by
Locations
- Europe
- Albania
- Andorra
- Austria
- Belarus
- Belgium
- Bosnia & Herzegovina
- Bulgaria
- Croatia
- Cyprus
- Czech Republic
- Denmark
- Estonia
- Faroe Islands
- Finland
- France
- Germany
- Greece
- Hungary
- Iceland
- Ireland
- Italy
- Kosovo
- Latvia
- Liechtenstein
- Lithuania
- Luxembourg
- Macedonia
- Malta
- Moldova
- Monaco
- Montenegro
- Netherlands
- Northern Ireland
- Norway
- Poland
- Portugal
- Romania
- San Marino
- Serbia
- Slovakia
- Slovenia
- Spain
- Sweden
- Switzerland
- Turkey
- Ukraine
- United Kingdom
- Vatican City
Drug Candidates Services In Europe
28 services found
Manufactured by:Inovotion Sas based inLa Tronche, FRANCE
Pharmaceutical chemical and biology researchers need to develop new methods and models to improve the predictivity of preclinical discovery phases and increase the number of good molecules in clinic. INOVOTION’s unique in vivo technology will allow you to raise the global number of drug candidates tested in clinic without increasing your ...
by:Solvias AG based inKaiseraugst, SWITZERLAND
Most drug substances are marketed as crystalline material. Having a crystalline drug candidate is beneficial to development processes and simplifies registration. We offer crystallization screening services and also complete crystallization development ...
by:Reaction Biology Corp. based inMalvern, PENNSYLVANIA (USA)
Cell-based assays are valuable to probe new drug candidates in the environment of intact cells with physiologic concentrations of substrates, co-factors and ...
Manufactured by:Creative Biolabs based inShirley, NEW YORK (USA)
ADMET stands as an abbreviation for absorption, distribution, metabolism, excretion, and toxicity in pharmacokinetics and pharmacology. These properties describe the reaction of a drug medication within an organism, human, or animal, which helps scientists evaluate their drug candidates and select compounds that are likely to have the desired ...
Manufactured by:Creative Biolabs based inShirley, NEW YORK (USA)
Antibody drugs which consist of antibody substances are prepared by antibody engineering technology based on cell and gene engineering technology. An important feature of antibody drugs is that they can be tailored making by genetic engineering and be prepared according to specific therapeutic needs. With the development of antibody genetic engineering ...
Manufactured by:Creative Biolabs based inShirley, NEW YORK (USA)
Prior to clinical trials, it is necessary to conduct animal toxicity studies to best characterize the potential toxicity of new drug candidates. Generally, the objective of preclinical safety evaluation is to determine the toxic effects with respect to target organs, dose dependency, the relationship between clinical findings and exposure to the compound, and ...
Manufactured by:Creative Bioarray based inShirley, NEW YORK (USA)
Pooled Human Hepatocytes are the chief functional cells of the liver, responsible for the selective uptake, metabolism and excretion of most drugs. Cells for use in plate cultures or suspension assays represent a key tool for predicting properties such as hepatotoxicity, metabolism, and potential drug-drug interactions. Since these cells mimic ...
Manufactured by:Creative Bioarray based inShirley, NEW YORK (USA)
Creative Bioarray offers the opportunity for highly predictable pre-clinical cardio-toxicity testing to help our customers to reduce both the cost and duration of bringing a new drug candidate to market. ...
Manufactured by:Inovotion Sas based inLa Tronche, FRANCE
Target validation is an essential and critical phase of the drug discovery process. This is a crucial step before starting to develop a treatment based on a targeted protein that has been identified to play a role in the disease. The target protein’s role must be clearly identified before starting to develop a drug candidate against the ...
Manufactured by:Atriva Therapeutics GmbH based inTübingen, GERMANY
The company’s lead drug candidate is the MEK inhibitor zapnometinib. The small molecule, which can be administered orally (tablet), is under advanced clinical development in two severe respiratory viral diseases: COVID-19 and influenza, two disease areas with urgent need for effective ...
Manufactured by:Galapagos NV based inMechelen, BELGIUM
This external research can supplement the comprehensive data generated in registration studies by supplying valuable information about the safety, efficacy, pharmacology and tolerability and economic value of our drug candidates and medicines. Galapagos supports external research through unsolicited funding requests. These are evaluated through our Investigator ...
Manufactured by:Creative Biolabs based inShirley, NEW YORK (USA)
Pharmacokinetics (PK) dedicated to determining the mechanisms of a drug's absorption, biodistribution, when it eliminated from the body and what it becomes. It is a study of how an organism affects a drug. In vivo PK studies are critical to ensure drug candidates have appropriate PK properties that can be evaluated in preclinical ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
Our approach is to identify functional and developable lead molecules and quickly proceed to verified animal disease models to study the direct impact of our drug candidates with clinically relevant read outs. We build our know-how by working on common pathways that are frequently used in this area, often with varying tissue specificity or multiple functionality ...
Manufactured by:CENTOGENE N.V. based inRostock, GERMANY
We work with partners to develop new disease models and new biomarkers of disease. We can also use our disease models to identify new drug targets and screen chemical compounds to identify potential new drug candidates. CENTOGENE provides companies with tools to accelerate drug discovery. From population screening studies that ...
Manufactured by:Invicro, LLC based inNeedham, MASSACHUSETTS (USA)
As part of the REALM IDx, Inc. group, our pathology service laboratories support projects spanning preclinical biomarker discovery research to clinical trials and development of companion diagnostics (CDx) products. Our scientific, operational and regulatory expertise enables us to deliver insights needed to take lead drug candidates to the next level. ...
by:Trion Research GmbH based inPuchheim, GERMANY
Moreover, we offer the full range of preclinical and clinical support from trial design over immunomonitoring and tumor biology analysis to data management and logistics solutions. We are particularly strong in supporting the development of innovative drugs. We work together with our partners to elucidate the modes of action of new compounds and to develop tailored approaches for ...
by:Trion Research GmbH based inPuchheim, GERMANY
Collaborations - In a team, you do better. We have established long-term partnerships with industry as well as several collaborations with leading academics in the disciplines that are relevant to the projects we support. We draw on the joint capabilities of this network to continuously improve our services and provide optimal assistance for each individual project at any ...
Manufactured by:Creative Bioarray based inShirley, NEW YORK (USA)
As compounds move from discovery to development, the need for even more detailed and precise metabolite data becomes increasingly important, both to understand the characteristics of the candidate drug in humans and to fulfill the regulatory requirements that will underpin a successful drug registration. Creative Bioarray has deep expertise in ...
by:PharmAI GmbH based inDresden, GERMANY
Increase your success rate at an early stage. With pharmAI's rapid off-target prediction service you can already find potential off-targets during the discovery ...
by:F. Hoffmann-La Roche Ltd. based inBasel, SWITZERLAND
Healthcare research has never been more important. Time and time again, our biomedical research and development (R&D) has resulted in products that have advanced the understanding of disease and transformed the practice of medicine. This has always been the lifeblood of our company, and our substantial investment in R&D reflects ...